28 slides from Dr. Lal Pathlabs's earnings presentation, Feb 1, 2024
Slide 1: Exchange filing cover letter
February 01, 2024 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Symbol: LALPATHLAB Scrip Code: 539524 Sub: Earning
Slide 2: Dr. Lal PathLabs Limited Q3 FY24 Results Presentation
Dr. Lal PathLabs Limited (DLPL) Q3 FY24 Results Presentation February 2024
Slide 3: Disclaimer
Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr Lal PathLabs Limited (the “Company”) for use in presentati
Slide 4: Table of Contents
Table of Contents DLPL - At a Glance 4 Q3 FY24 Performance Overview 5 Financials 6 Operating Highlights 7 Management Commentary 9 Corporate Overview 10 Shareholding 25 Contact Us 27 DISCLAIMER: This presentation may contain ‘forward-looking’ statements at places. The Company’s business operations re
Slide 5: Dr. Lal PathLabs – At a Glance
Dr. Lal PathLabs – At a Glance 15% 24% 120% 5,191 277 5,102 3 Year Revenue ROCE Equity Dividend for Pathology & Labs; Geographically Patient Service CAGR Excl. Cash & FY22-23 Radiology tests; spread-out network Centers (PSC’s) Investments Comprehensive Test menu 70+ years of experience in 111 Mn pat
Slide 6: Q3 FY24 Performance Overview
Q3 FY24 Performance Overview Q3 FY24 Q3 FY23 10.1% Rs. 539 crore Revenue Rs. 489 crore 24.6% Rs. 141 crore EBITDA Rs. 113 crore 53.3% Rs. 82 crore PAT Rs. 54 crore +1% 20% SwasthFit 19% Contr. +364 Cr Rs. 853 crore Cash Rs. 489 crore Classification: Restricted 5 Classification: Restricted
Slide 7: Financials
Financials Particulars (Rs. Cr.) Q3 FY24 Q3 FY23 Gr % YTD Dec’23 YTD Dec’22 Gr % Revenue 539 489 10.1% 1,681 1,526 10.2% Operating Expenditure 398 376 1,217 1,152 EBITDA 141 113 24.6% 465 374 24.1% Margins 26.1% 23.1% 27.6% 24.5% Other Income 18 11 51 28 Depreciation 36 38 107 113 EBIT 123 86 43.8%
Slide 8: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs No. of PUPs +61 +2,007 +3,943 277 277 4,731 5,102 9,247 10,599 10,938 216 231 3,705 3,095 6,995 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 No. of Patients (Mn) No. of Samples (Mn) +39% +52% 27.3 26.9 66.0 72.3 59.1 19.4 2
Slide 9: Increasing DLPL reach in Tier 3+
Increasing DLPL reach in Tier 3+ Particulars FY20 FY21 FY22 FY 23 Revenue Tier 3+ 421 544 683 685 18% 15% Tier 3+ CAGR Total CAGR Total DLPL Revenue 1,330 1,581 2,087 2,,017 % Revenue from Tier 3+ 32% 34% 33% 34% +2% Contribution from Tier 3+ Infra Count in Tier 3+ Labs 60 64 69 70 +10 Labs CCs 1,76
Slide 10: Management Commentary
Management Commentary Commenting on the performance, (Hony) Brig. Dr. Commenting on the performance, Dr. Om Manchanda, Commenting on the performance, Mr. Bharath Arvind Lal, Executive Chairman said: Managing Director said: Uppiliappan, Chief Executive Officer said: “Dr. Lal Pathlabs continues to be
Slide 11: Corporate Overview
WIDENING “0:26 HORIZONS Ox Lat Pathlabs D (3) y SERVING BETTER Corporate Overview
Slide 12: Overview of Dr. Lal PathLabs
Overview of Dr. Lal PathLabs Established Established consumer healthcare brand in diagnostic services brand Pan-India 277 clinical labs (including National Reference Lab at Delhi and Well-positioned integrated Regional Reference labs at Kolkata, Bangalore & Mumbai), 5,102 coverage Patient Service Ce
Slide 13: ABDM - All Milestones achieved, DLPL among early adopters
ABDM - All Milestones acheived, DLPL among early adopters Ayushman Bharat Digital Mission aims to create a National Digital Health Ecosystem to bridge the existing gap amongst different stakeholders of Healthcare ecosystem through digital highways. The mission also enables interoperability and porta
Slide 14: Vision, Mission & Values
Vision, Mission & Values Be the most trusted Customer First healthcare partner, enabling healthier lives VISION Ethics & Integrity To be an undisputed market Quality leader by providing accessible, affordable, timely and quality VALUES healthcare, diagnostics, applying Accountability insights and cu
Slide 15: DLPL Strategy for future growth
DLPL Strategy for future growth Significantly leverage the Enhance high-end test portfolio of strong digital infrastructure super-specialty & bundled test • Deployed AI, data analytics, machine learning • Created specialty verticals like Genevolve to focus on tools to elevate the patient experience
Slide 16: Leveraging digital infrastructure to make life easier for patient
Leveraging digital infrastructure to make life easier for patient New Website Launch Wallet • New age user intuitive website. • Senior Citizen Wallet: Wallet points on every • Responsive , mobile friendly web designs. booking for Senior Citizen Patients. • SEO friendly for improved customer reach •
Slide 17: Summary highlights – Technical Lab Operations
Summary highlights – Technical Lab Operations LACE and the centre Only lab in India to introduce the First lab to introduce the of excellence in Relaunched the Lipid Donor derived cell free DNA ONCOPRO TSO500 Reproductive panels incorporating the (LIQUID BIOPSY) technique for Comprehensive Genomic m
Slide 18: Genevolve: Genetic Testing Division
Genevolve: Genetic Testing Division Onco Genomics Successful completion of 3 years of Launch Wide Test offering with 160+ New Tests Neuro Genomics Wellness Genomics & Pharmacogenomics are upcoming segment Direct reach of 3000+ Doctors Reproductive Genomics Dedicated Business Development team for Gen
Slide 19: Highest Quality Standards in the Industry
Highest Quality Standards in the Industry Best in the Industry CAP Proficiency Testing Score at 99.5% for National Reference Lab Consistently high EQAS Performance Testing Score at 98.5% for Satellite Labs CAP accreditation 2 labs, NABL accreditation 36 Labs 100+ Quality Digitally enabled Real time
Slide 20: Quality Control, Laboratory excellence, Capability building
Quality Control Laboratory excellence Capability building Test Recommendation engine NABL 133 implementation D L Shah Gold Award for LPL Project ‘Improving Laboratory Performance by developing an in-house automated process to Risk Based Internal Audits monitor Quality control’ PROJECT NEEV- self lea
Slide 21: Enhanced Customer Experience in Home Collection
Enhanced Customer Experience in Home Collection Real time 30 minutes slot visibility & booking D2C- Automated lead management for the patient Digital ID card & ratings of Phlebo Auto Routing engine to dynamically to the patient allocate the booking to nearest available phlebotomist Variable model wh
Slide 22: Key ESG Initiatives
Key ESG Initiatives Use of Solar Panels Use of Electric E-billing and e- for Power; addition bikes for sample payment receipt to of 50 KW solar collection reduce paper usage plant at NRL Data centre Water saving through virtualization to treatment & reuse of prevent heat and wastewater CO2 emission
Slide 23: Savings of >1.3 million aliquots and >5210 tons of plastic waste
Savings of >1.3 million aliquots and >5210 tons of plastic waste in our lab – a strong commitment to sustainability Dr. Lal Pathlabs’ leadership vision focuses on continuous We reduced the need for aliquots by 93% by replacing our previous system configuration1,2 with new, improvement while maintain
Slide 24: Cyber Security Capability
Cyber Security Capability Data Loss • State-of-the-art data loss prevention technology to monitor and prevent the disclosure of information Prevention • Data classification platform for information labeling and handling according to severity of data • Rights management system to enable persistent da
Slide 25: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Bharath Uppiliappan Ved Prakash Goel Executive Chairman Managing Director Whole-time Director Chief Executive Officer Group Chief Financial Officer Shankha Banerjee Munender Soperna Jai Prakash Meena Manoj Garg
Slide 26: Shareholding as of 31st December, 2023
Shareholding as of 31st December, 2023 25.7% FPI’s & NRI’s 54.6% Promoter and Promoter 13.2% Group Others 6.5% Mutual Funds* *Mutual Funds includes Alternate Investment Funds as well 25 25 Classification: Restricted
Slide 27: Key Awards & Recognition
Key Awards & Recognition Diagnostic Chain of the Gold Award Year – West Top 100 Global Most Loved QCI – D. L. Shah Quality Business Standard Star SME Best Brands Healthcare GAPIO Excellence in Awarded by the Workplace 2023 Awards - 2022 of the year 2022 2022 Diagnostics Award 2022 prestigious Health
Slide 28: Contact Us
Contact Us About Dr. Lal PathLabs Limited (DLPL) Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests